# DCN

## Overview
The DCN gene encodes decorin, a small leucine-rich proteoglycan (SLRP) that plays a pivotal role in the structural and functional integrity of the extracellular matrix. Decorin is characterized by its leucine-rich repeats (LRRs) and is involved in collagen fibrillogenesis, where it regulates the formation and spacing of collagen fibrils, particularly type I collagen, thereby influencing tissue mechanics and integrity (Danielson1997Targeted). Beyond its structural role, decorin interacts with various growth factors and receptors, modulating cellular processes such as proliferation, migration, and apoptosis, which are crucial for tissue homeostasis and repair (Kubo2022Role). Decorin's interactions with signaling molecules like transforming growth factor-β (TGF-β) and epidermal growth factor receptor (EGFR) underscore its significance in cellular signaling pathways and its potential as a therapeutic target in fibrotic diseases and cancer (Hu2021Decorinmediated; Järvinen2015Decorin:).

## Structure
Decorin (DCN) is a small leucine-rich proteoglycan (SLRP) characterized by a core protein of approximately 40 kDa, which includes leucine-rich repeats (LRRs) of about 12 amino acids each (IMAI1997Degradation). The primary structure of decorin consists of these LRRs, which are a common feature of the SLRP family, including biglycan, fibromodulin, and lumican (IMAI1997Degradation). The secondary structure of decorin is characterized by a solenoid fold, with a continuous beta-sheet on the concave side and various secondary helical structures on the convex side (Bella2008The). The tertiary structure forms a horseshoe shape, which is typical for LRR proteins (Bella2008The).

Decorin often exists as a homodimer, with the concave side of the LRR domains serving as the dimerization interface (Bella2008The). This dimerization is essential for the stability of decorin at physiological temperatures (Bella2008The). Decorin is covalently linked with a single glycosaminoglycan (GAG) chain, which can be either chondroitin or dermatan sulfate, depending on the tissue (Seidler2012The). This GAG chain undergoes various modifications, such as sulfation, contributing to the functional microheterogeneity of the chains (Seidler2012The). Decorin's structure allows it to function in matrix organization, collagen fibrillogenesis, and cell signaling (Seidler2012The).

## Function
Decorin, encoded by the DCN gene, is a small leucine-rich proteoglycan that plays a crucial role in maintaining the structural integrity and mechanical properties of connective tissues. It is primarily involved in collagen fibrillogenesis, where it binds noncovalently to fibrillar collagen, particularly type I, to regulate collagen fibril formation and maintain interfibrillar spacing (Danielson1997Targeted). This regulation is essential for proper tissue mechanics, as evidenced by decorin-deficient mice, which exhibit irregular collagen fibrils and reduced tensile strength in skin and tendon tissues (Danielson1997Targeted).

Decorin also interacts with various growth factors and receptors, influencing cell proliferation, migration, and apoptosis. It binds to transforming growth factor-β (TGF-β) and modulates its interaction with receptors, impacting cell growth and signaling pathways related to fibrotic diseases (Kubo2022Role). In the context of the extracellular matrix, decorin acts as a reservoir for growth factors, sequestering signaling molecules and modulating processes such as wound healing and angiogenesis (Kubo2022Role).

In addition to its structural role, decorin is involved in cellular signaling pathways. It interacts with the insulin-like growth factor I receptor (IGF-IR), leading to enhanced phosphorylation of protein kinase B (Akt) and induction of cyclin-dependent kinase inhibitors, which regulate cell death and synthesis of matrix constituents (Schaefer2008Biological). Decorin's ability to modulate these pathways highlights its importance in maintaining tissue homeostasis and preventing pathological changes in healthy human cells.

## Clinical Significance
Mutations and alterations in the expression of the DCN gene, which encodes the proteoglycan decorin, are associated with several diseases and conditions. In the context of cancer, decorin acts as a tumor suppressor. Its downregulation is observed in various cancers, including colorectal cancer and inflammatory breast cancer, where it is linked to increased tumor aggressiveness and metastasis (Hu2021Decorinmediated; Mlakar2009Presence). Decorin's tumor-suppressive functions are mediated through pathways that inhibit cell proliferation and migration, such as the EGFR/ERK signaling pathway (Hu2021Decorinmediated).

In connective tissue disorders, decorin deficiency in mice results in collagen fibril abnormalities similar to those seen in Ehlers-Danlos syndrome, characterized by skin fragility and altered collagen morphology (Ameye2002Mice; Mizumoto2017Pathophysiological). Although no direct human cases of Ehlers-Danlos syndrome have been linked to DCN mutations, decorin's role in collagen fibrillogenesis suggests its potential involvement in related conditions (Mizumoto2017Pathophysiological).

In eye health, decorin is implicated in glaucoma pathogenesis. Its deficiency leads to increased expression of growth factors like TGF-β2, contributing to extracellular matrix disorganization and tissue stiffness in the optic nerve head, a hallmark of glaucoma (Schneider2021Decorin—An). Decorin mutations also cause congenital stromal corneal dystrophy, characterized by corneal clouding due to abnormal collagen fibrils (Mizumoto2017Pathophysiological).

## Interactions
Decorin (DCN) is a small leucine-rich proteoglycan that engages in various interactions with proteins, influencing multiple biological processes. It binds noncovalently to the surface of fibrillar collagen, particularly type I, playing a crucial role in collagen fibrillogenesis and maintaining interfibrillar spacing (Danielson1997Targeted). Decorin also interacts with other collagen types, including II, III, and VI, as well as fibronectin, C1q, and transforming growth factor-β (TGF-β), suggesting its importance in maintaining extracellular matrix integrity and regulating cell proliferation (Danielson1997Targeted).

Decorin is known to bind directly to the epidermal growth factor receptor (EGFR) and inhibit its activity, as well as the activity of other ErbB family members (Järvinen2015Decorin:). It also interacts with c-Met, the hepatocyte growth factor receptor, and inhibits the vascular endothelial growth factor receptor 2 (VEGFR2) and the insulin-like growth factor-1 receptor (IGF-IR) (Järvinen2015Decorin:). In inflammatory breast cancer, decorin interacts with E-cadherin, accelerating its degradation through an autophagy-linked lysosomal pathway, which negatively regulates the E-cadherin/EGFR/ERK axis (Hu2021Decorinmediated). Decorin also binds to platelet-derived growth factor (PDGF), forming a specific complex that may influence PDGF-stimulated vascular smooth muscle cell functions (Nili2003Decorin).


## References


[1. (Schaefer2008Biological) Liliana Schaefer and Renato V. Iozzo. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. Journal of Biological Chemistry, 283(31):21305–21309, August 2008. URL: http://dx.doi.org/10.1074/jbc.r800020200, doi:10.1074/jbc.r800020200. This article has 403 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.r800020200)

[2. (Bella2008The) J. Bella, K. L. Hindle, P. A. McEwan, and S. C. Lovell. The leucine-rich repeat structure. Cellular and Molecular Life Sciences, 65(15):2307–2333, April 2008. URL: http://dx.doi.org/10.1007/S00018-008-8019-0, doi:10.1007/s00018-008-8019-0. This article has 582 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/S00018-008-8019-0)

[3. (Danielson1997Targeted) Keith G. Danielson, Helene Baribault, David F. Holmes, Helen Graham, Karl E. Kadler, and Renato V. Iozzo. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. The Journal of Cell Biology, 136(3):729–743, February 1997. URL: http://dx.doi.org/10.1083/jcb.136.3.729, doi:10.1083/jcb.136.3.729. This article has 1136 citations.](https://doi.org/10.1083/jcb.136.3.729)

[4. (Mlakar2009Presence) Vid Mlakar, Gašper Berginc, Metka Volavšek, Zdravko Štor, Miran Rems, and Damjan Glavač. Presence of activating kras mutations correlates significantly with expression of tumour suppressor genes dcn and tpm1 in colorectal cancer. BMC Cancer, August 2009. URL: http://dx.doi.org/10.1186/1471-2407-9-282, doi:10.1186/1471-2407-9-282. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2407-9-282)

[5. (Seidler2012The) Daniela G Seidler. The galactosaminoglycan-containing decorin and its impact on diseases. Current Opinion in Structural Biology, 22(5):578–582, October 2012. URL: http://dx.doi.org/10.1016/j.sbi.2012.07.012, doi:10.1016/j.sbi.2012.07.012. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.sbi.2012.07.012)

[6. (Mizumoto2017Pathophysiological) Shuji Mizumoto, Tomoki Kosho, Shuhei Yamada, and Kazuyuki Sugahara. Pathophysiological significance of dermatan sulfate proteoglycans revealed by human genetic disorders. Pharmaceuticals, 10(2):34, March 2017. URL: http://dx.doi.org/10.3390/ph10020034, doi:10.3390/ph10020034. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ph10020034)

[7. (Kubo2022Role) Eri Kubo, Shinsuke Shibata, Teppei Shibata, Hiroshi Sasaki, and Dhirendra P. Singh. Role of decorin in the lens and ocular diseases. Cells, 12(1):74, December 2022. URL: http://dx.doi.org/10.3390/cells12010074, doi:10.3390/cells12010074. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12010074)

[8. (IMAI1997Degradation) Kazushi IMAI, Ari HIRAMATSU, Daikichi FUKUSHIMA, Michael D. PIERSCHBACHER, and Yasunori OKADA. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release. Biochemical Journal, 322(3):809–814, March 1997. URL: http://dx.doi.org/10.1042/bj3220809, doi:10.1042/bj3220809. This article has 331 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj3220809)

[9. (Schneider2021Decorin—An) Magdalena Schneider, Andrea E. Dillinger, Andreas Ohlmann, Renato V. Iozzo, and Rudolf Fuchshofer. Decorin—an antagonist of tgf-β in astrocytes of the optic nerve. International Journal of Molecular Sciences, 22(14):7660, July 2021. URL: http://dx.doi.org/10.3390/ijms22147660, doi:10.3390/ijms22147660. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms22147660)

[10. (Nili2003Decorin) Nafiseh Nili, Asim N. Cheema, Frank J. Giordano, Alan W. Barolet, Saeid Babaei, Reed Hickey, Mohammad R. Eskandarian, Mirjam Smeets, Jagdish Butany, Gerard Pasterkamp, and Bradley H. Strauss. Decorin inhibition of pdgf-stimulated vascular smooth muscle cell function. The American Journal of Pathology, 163(3):869–878, September 2003. URL: http://dx.doi.org/10.1016/s0002-9440(10)63447-5, doi:10.1016/s0002-9440(10)63447-5. This article has 93 citations.](https://doi.org/10.1016/s0002-9440(10)63447-5)

[11. (Järvinen2015Decorin:) Tero A. H. Järvinen and Stuart Prince. Decorin: a growth factor antagonist for tumor growth inhibition. BioMed Research International, 2015:1–11, 2015. URL: http://dx.doi.org/10.1155/2015/654765, doi:10.1155/2015/654765. This article has 79 citations and is from a poor quality or predatory journal.](https://doi.org/10.1155/2015/654765)

[12. (Hu2021Decorinmediated) Xiaoding Hu, Emilly S. Villodre, Richard Larson, Omar M. Rahal, Xiaoping Wang, Yun Gong, Juhee Song, Savitri Krishnamurthy, Naoto T. Ueno, Debu Tripathy, Wendy A. Woodward, and Bisrat G. Debeb. Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. Communications Biology, January 2021. URL: http://dx.doi.org/10.1038/s42003-020-01590-0, doi:10.1038/s42003-020-01590-0. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s42003-020-01590-0)

[13. (Ameye2002Mice) L. Ameye and M. F. Young. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, ehlers-danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology, 12(9):107R-116R, September 2002. URL: http://dx.doi.org/10.1093/glycob/cwf065, doi:10.1093/glycob/cwf065. This article has 334 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/glycob/cwf065)